Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 616

1.

NK Cell-Based Immunotherapy for Hematological Malignancies.

Sivori S, Meazza R, Quintarelli C, Carlomagno S, Della Chiesa M, Falco M, Moretta L, Locatelli F, Pende D.

J Clin Med. 2019 Oct 16;8(10). pii: E1702. doi: 10.3390/jcm8101702. Review.

PMID:
31623224
2.

PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.

Tumino N, Besi F, Di Pace AL, Mariotti FR, Merli P, Li Pira G, Galaverna F, Pitisci A, Ingegnere T, Pelosi A, Quatrini L, Munari E, Locatelli F, Moretta L, Vacca P.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0585-7. [Epub ahead of print] No abstract available.

PMID:
31586150
3.

NK Cell Precursors in Human Bone Marrow in Health and Inflammation.

Bozzano F, Perrone C, Moretta L, De Maria A.

Front Immunol. 2019 Aug 28;10:2045. doi: 10.3389/fimmu.2019.02045. eCollection 2019. Review.

4.

Different Features of Tumor-Associated NK Cells in Patients With Low-Grade or High-Grade Peritoneal Carcinomatosis.

Pesce S, Belgrano V, Greppi M, Carlomagno S, Squillario M, Barla A, Della Chiesa M, Di Domenico S, Mavilio D, Moretta L, Candiani S, Sivori S, De Cian F, Marcenaro E.

Front Immunol. 2019 Aug 21;10:1963. doi: 10.3389/fimmu.2019.01963. eCollection 2019.

5.

HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition.

Furfaro AL, Ottonello S, Loi G, Cossu I, Piras S, Spagnolo F, Queirolo P, Marinari UM, Moretta L, Pronzato MA, Mingari MC, Pietra G, Nitti M.

Int J Cancer. 2019 Aug 3. doi: 10.1002/ijc.32611. [Epub ahead of print]

PMID:
31376303
6.

An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.

Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, Falco M, Pessino A, Muccio L, De Maria A, Marcenaro E, Moretta L, Sivori S.

Front Immunol. 2019 Jun 19;10:1415. doi: 10.3389/fimmu.2019.01415. eCollection 2019. Review.

7.

Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.

Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, Bertaina A, Moretta F, Del Zotto G, Pietra G, Mingari MC, Locatelli F, Moretta L.

Front Immunol. 2019 May 28;10:1179. doi: 10.3389/fimmu.2019.01179. eCollection 2019. Review.

8.

PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.

Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E.

Front Immunol. 2019 Jun 4;10:1242. doi: 10.3389/fimmu.2019.01242. eCollection 2019. Review.

9.

PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.

Munari E, Zamboni G, Lunardi G, Marconi M, Brunelli M, Martignoni G, Netto GJ, Quatrini L, Vacca P, Moretta L, Bogina G.

Hum Pathol. 2019 Aug;90:54-59. doi: 10.1016/j.humpath.2019.05.003. Epub 2019 May 21.

PMID:
31121194
10.

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.

Ingegnere T, Mariotti FR, Pelosi A, Quintarelli C, De Angelis B, Tumino N, Besi F, Cantoni C, Locatelli F, Vacca P, Moretta L.

Front Immunol. 2019 Apr 30;10:957. doi: 10.3389/fimmu.2019.00957. eCollection 2019.

11.

Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions.

Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L.

Front Immunol. 2019 Apr 26;10:910. doi: 10.3389/fimmu.2019.00910. eCollection 2019. Review.

12.

NKp44-NKp44 Ligand Interactions in the Regulation of Natural Killer Cells and Other Innate Lymphoid Cells in Humans.

Parodi M, Favoreel H, Candiano G, Gaggero S, Sivori S, Mingari MC, Moretta L, Vitale M, Cantoni C.

Front Immunol. 2019 Apr 9;10:719. doi: 10.3389/fimmu.2019.00719. eCollection 2019. Review.

13.

Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor.

Tumino N, Martini S, Munari E, Scordamaglia F, Besi F, Mariotti FR, Bogina G, Mingari MC, Vacca P, Moretta L.

Int J Cancer. 2019 Sep 15;145(6):1660-1668. doi: 10.1002/ijc.32262. Epub 2019 Mar 26.

14.

Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).

Falco M, Pende D, Munari E, Vacca P, Mingari MC, Moretta L.

HLA. 2019 Apr;93(4):185-194. doi: 10.1111/tan.13509. Review.

15.

Heterogeneity of NK Cells and Other Innate Lymphoid Cells in Human and Murine Decidua.

Vacca P, Chiossone L, Mingari MC, Moretta L.

Front Immunol. 2019 Feb 8;10:170. doi: 10.3389/fimmu.2019.00170. eCollection 2019. Review.

16.

Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.

Sivori S, Vacca P, Del Zotto G, Munari E, Mingari MC, Moretta L.

Cell Mol Immunol. 2019 May;16(5):430-441. doi: 10.1038/s41423-019-0206-4. Epub 2019 Feb 18. Review.

PMID:
30778167
17.

PD-1 is expressed by and regulates human group 3 innate lymphoid cells in human decidua.

Vacca P, Pesce S, Greppi M, Fulcheri E, Munari E, Olive D, Mingari MC, Moretta A, Moretta L, Marcenaro E.

Mucosal Immunol. 2019 May;12(3):624-631. doi: 10.1038/s41385-019-0141-9. Epub 2019 Feb 12.

PMID:
30755717
18.

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression.

Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, Munari E, Pesce S, Marcenaro E, Moretta A, Vacca P, Moretta L.

Oncoimmunology. 2018 Dec 25;8(3):1557030. doi: 10.1080/2162402X.2018.1557030. eCollection 2019.

19.

Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.

Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G.

Oncotarget. 2018 Dec 11;9(97):37077. doi: 10.18632/oncotarget.26475. eCollection 2018 Dec 11.

20.

Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board.

Mingari MC, Pietra G, Moretta L.

Trends Immunol. 2019 Feb;40(2):83-85. doi: 10.1016/j.it.2018.12.009. Epub 2019 Jan 1.

PMID:
30609967
21.

Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.

Munari E, Zamboni G, Sighele G, Marconi M, Sommaggio M, Lunardi G, Rossi G, Cavazza A, Moretta F, Gilioli E, Caliò A, Netto GJ, Hoque MO, Martignoni G, Brunelli M, Vacca P, Moretta L, Bogina G.

Cancer Cytopathol. 2019 Feb;127(1):52-61. doi: 10.1002/cncy.22083. Epub 2018 Nov 30.

PMID:
30500997
22.

Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration.

Parodi M, Raggi F, Cangelosi D, Manzini C, Balsamo M, Blengio F, Eva A, Varesio L, Pietra G, Moretta L, Mingari MC, Vitale M, Bosco MC.

Front Immunol. 2018 Oct 16;9:2358. doi: 10.3389/fimmu.2018.02358. eCollection 2018.

23.

Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes?

Vacca P, Munari E, Tumino N, Moretta F, Pietra G, Vitale M, Del Zotto G, Mariotti FR, Mingari MC, Moretta L.

Immunol Lett. 2018 Sep;201:14-19. doi: 10.1016/j.imlet.2018.11.004. Epub 2018 Nov 12. Review.

24.

Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.

Damele L, Montaldo E, Moretta L, Vitale C, Mingari MC.

Front Immunol. 2018 Oct 23;9:2433. doi: 10.3389/fimmu.2018.02433. eCollection 2018.

25.

New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression.

Pesce S, Squillario M, Greppi M, Loiacono F, Moretta L, Moretta A, Sivori S, Castagnola P, Barla A, Candiani S, Marcenaro E.

Front Immunol. 2018 Oct 15;9:2360. doi: 10.3389/fimmu.2018.02360. eCollection 2018.

26.

Molecular definition of group 1 innate lymphoid cells in the mouse uterus.

Filipovic I, Chiossone L, Vacca P, Hamilton RS, Ingegnere T, Doisne JM, Hawkes DA, Mingari MC, Sharkey AM, Moretta L, Colucci F.

Nat Commun. 2018 Oct 29;9(1):4492. doi: 10.1038/s41467-018-06918-3.

27.

Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor.

Gaggero S, Bruschi M, Petretto A, Parodi M, Del Zotto G, Lavarello C, Prato C, Santucci L, Barbuto A, Bottino C, Candiano G, Moretta A, Vitale M, Moretta L, Cantoni C.

Oncoimmunology. 2018 Jul 11;7(9):e1470730. doi: 10.1080/2162402X.2018.1470730. eCollection 2018.

28.

Human Innate Lymphoid Cells: Their Functional and Cellular Interactions in Decidua.

Vacca P, Vitale C, Munari E, Cassatella MA, Mingari MC, Moretta L.

Front Immunol. 2018 Aug 14;9:1897. doi: 10.3389/fimmu.2018.01897. eCollection 2018. Review.

29.

PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.

Munari E, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Mariotti FR, Vacca P, Moretta L, Bogina G.

Oncotarget. 2018 Jul 13;9(54):30465-30471. doi: 10.18632/oncotarget.25770. eCollection 2018 Jul 13.

30.

Analysis of KIR3DP1 Polymorphism Provides Relevant Information on Centromeric KIR Gene Content.

Bono M, Pende D, Bertaina A, Moretta A, Della Chiesa M, Sivori S, Zecca M, Locatelli F, Moretta L, Bottino C, Falco M.

J Immunol. 2018 Sep 1;201(5):1460-1467. doi: 10.4049/jimmunol.1800564. Epub 2018 Aug 1.

31.

The yin-yang of the interaction between myelomonocytic cells and NK cells.

Molgora M, Supino D, Mavilio D, Santoni A, Moretta L, Mantovani A, Garlanda C.

Scand J Immunol. 2018 Sep;88(3):e12705. doi: 10.1111/sji.12705. Epub 2018 Aug 19. Review.

32.

PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.

Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, Netto GJ, Hoque MO, Brunelli M, Martignoni G, Haffner MC, Moretta F, Pegoraro MC, Cavazza A, Samogin G, Furlan V, Mariotti FR, Vacca P, Moretta L, Bogina G.

Am J Surg Pathol. 2018 Oct;42(10):1384-1389. doi: 10.1097/PAS.0000000000001105.

PMID:
29901568
33.

Late Development of FcεRγneg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients.

Muccio L, Falco M, Bertaina A, Locatelli F, Frassoni F, Sivori S, Moretta L, Moretta A, Della Chiesa M.

Front Immunol. 2018 May 15;9:1050. doi: 10.3389/fimmu.2018.01050. eCollection 2018.

34.

Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias.

Pistoia V, Tumino N, Vacca P, Veneziani I, Moretta A, Locatelli F, Moretta L.

Front Immunol. 2018 May 7;9:984. doi: 10.3389/fimmu.2018.00984. eCollection 2018. Review.

35.

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.

Locatelli F, Pende D, Falco M, Della Chiesa M, Moretta A, Moretta L.

Trends Immunol. 2018 Jul;39(7):577-590. doi: 10.1016/j.it.2018.04.009. Epub 2018 May 21. Review.

PMID:
29793748
36.

NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.

Huergo-Zapico L, Parodi M, Cantoni C, Lavarello C, Fernández-Martínez JL, Petretto A, DeAndrés-Galiana EJ, Balsamo M, López-Soto A, Pietra G, Bugatti M, Munari E, Marconi M, Mingari MC, Vermi W, Moretta L, González S, Vitale M.

Cancer Res. 2018 Jul 15;78(14):3913-3925. doi: 10.1158/0008-5472.CAN-17-1891. Epub 2018 May 11.

37.

PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.

Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Hoque MO, Moretta F, Mingari MC, Pegoraro MC, Inno A, Paiano S, Terzi A, Cavazza A, Rossi G, Mariotti FR, Vacca P, Moretta L, Bogina G.

J Thorac Oncol. 2018 Aug;13(8):1113-1120. doi: 10.1016/j.jtho.2018.04.017. Epub 2018 Apr 25. Erratum in: J Thorac Oncol. 2019 Apr;14(4):744.

38.

Alessandro Moretta 1953-2018.

Moretta L, Mantovani A.

Nat Immunol. 2018 Apr;19(4):315. doi: 10.1038/s41590-018-0075-5. No abstract available.

PMID:
29563619
39.

PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.

Munari E, Zamboni G, Marconi M, Sommaggio M, Brunelli M, Martignoni G, Netto GJ, Moretta F, Mingari MC, Salgarello M, Terzi A, Picece V, Pomari C, Lunardi G, Cavazza A, Rossi G, Moretta L, Bogina G.

Oncotarget. 2017 Oct 4;8(52):90123-90131. doi: 10.18632/oncotarget.21485. eCollection 2017 Oct 27. Erratum in: Oncotarget. 2018 Dec 11;9(97):37077.

40.

Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective.

Cifaldi L, Locatelli F, Marasco E, Moretta L, Pistoia V.

Trends Mol Med. 2017 Dec;23(12):1156-1175. doi: 10.1016/j.molmed.2017.10.002. Epub 2017 Nov 10. Review.

PMID:
29133133
41.

Guidelines for the use of flow cytometry and cell sorting in immunological studies.

Cossarizza A, Chang HD, Radbruch A, Akdis M, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, Boulais PE, Brinkman RR, Büscher M, Busch DH, Bushnell TP, Cao X, Cavani A, Chattopadhyay PK, Cheng Q, Chow S, Clerici M, Cooke A, Cosma A, Cosmi L, Cumano A, Dang VD, Davies D, De Biasi S, Del Zotto G, Della Bella S, Dellabona P, Deniz G, Dessing M, Diefenbach A, Di Santo J, Dieli F, Dolf A, Donnenberg VS, Dörner T, Ehrhardt GRA, Endl E, Engel P, Engelhardt B, Esser C, Everts B, Dreher A, Falk CS, Fehniger TA, Filby A, Fillatreau S, Follo M, Förster I, Foster J, Foulds GA, Frenette PS, Galbraith D, Garbi N, García-Godoy MD, Geginat J, Ghoreschi K, Gibellini L, Goettlinger C, Goodyear CS, Gori A, Grogan J, Gross M, Grützkau A, Grummitt D, Hahn J, Hammer Q, Hauser AE, Haviland DL, Hedley D, Herrera G, Herrmann M, Hiepe F, Holland T, Hombrink P, Houston JP, Hoyer BF, Huang B, Hunter CA, Iannone A, Jäck HM, Jávega B, Jonjic S, Juelke K, Jung S, Kaiser T, Kalina T, Keller B, Khan S, Kienhöfer D, Kroneis T, Kunkel D, Kurts C, Kvistborg P, Lannigan J, Lantz O, Larbi A, LeibundGut-Landmann S, Leipold MD, Levings MK, Litwin V, Liu Y, Lohoff M, Lombardi G, Lopez L, Lovett-Racke A, Lubberts E, Ludewig B, Lugli E, Maecker HT, Martrus G, Matarese G, Maueröder C, McGrath M, McInnes I, Mei HE, Melchers F, Melzer S, Mielenz D, Mills K, Mirrer D, Mjösberg J, Moore J, Moran B, Moretta A, Moretta L, Mosmann TR, Müller S, Müller W, Münz C, Multhoff G, Munoz LE, Murphy KM, Nakayama T, Nasi M, Neudörfl C, Nolan J, Nourshargh S, O'Connor JE, Ouyang W, Oxenius A, Palankar R, Panse I, Peterson P, Peth C, Petriz J, Philips D, Pickl W, Piconese S, Pinti M, Pockley AG, Podolska MJ, Pucillo C, Quataert SA, Radstake TRDJ, Rajwa B, Rebhahn JA, Recktenwald D, Remmerswaal EBM, Rezvani K, Rico LG, Robinson JP, Romagnani C, Rubartelli A, Ruckert B, Ruland J, Sakaguchi S, Sala-de-Oyanguren F, Samstag Y, Sanderson S, Sawitzki B, Scheffold A, Schiemann M, Schildberg F, Schimisky E, Schmid SA, Schmitt S, Schober K, Schüler T, Schulz AR, Schumacher T, Scotta C, Shankey TV, Shemer A, Simon AK, Spidlen J, Stall AM, Stark R, Stehle C, Stein M, Steinmetz T, Stockinger H, Takahama Y, Tarnok A, Tian Z, Toldi G, Tornack J, Traggiai E, Trotter J, Ulrich H, van der Braber M, van Lier RAW, Veldhoen M, Vento-Asturias S, Vieira P, Voehringer D, Volk HD, von Volkmann K, Waisman A, Walker R, Ward MD, Warnatz K, Warth S, Watson JV, Watzl C, Wegener L, Wiedemann A, Wienands J, Willimsky G, Wing J, Wurst P, Yu L, Yue A, Zhang Q, Zhao Y, Ziegler S, Zimmermann J.

Eur J Immunol. 2017 Oct;47(10):1584-1797. doi: 10.1002/eji.201646632. No abstract available.

42.

Peripheral Blood Mononuclear Cell Immunophenotyping in Fibrodysplasia Ossificans Progressiva Patients: Evidence for Monocyte DNAM1 Up-regulation.

Del Zotto G, Antonini F, Azzari I, Ortolani C, Tripodi G, Giacopelli F, Cappato S, Moretta L, Ravazzolo R, Bocciardi R.

Cytometry B Clin Cytom. 2018 Jul;94(4):613-622. doi: 10.1002/cyto.b.21594. Epub 2017 Nov 15.

43.

A conserved energetic footprint underpins recognition of human leukocyte antigen-E by two distinct αβ T cell receptors.

Sullivan LC, Walpole NG, Farenc C, Pietra G, Sum MJW, Clements CS, Lee EJ, Beddoe T, Falco M, Mingari MC, Moretta L, Gras S, Rossjohn J, Brooks AG.

J Biol Chem. 2017 Dec 22;292(51):21149-21158. doi: 10.1074/jbc.M117.807719. Epub 2017 Sep 25.

44.

Control of the HIV-1 DNA Reservoir Is Associated In Vivo and In Vitro with NKp46/NKp30 (CD335 CD337) Inducibility and Interferon Gamma Production by Transcriptionally Unique NK Cells.

Marras F, Casabianca A, Bozzano F, Ascierto ML, Orlandi C, Di Biagio A, Pontali E, Dentone C, Orofino G, Nicolini L, Taramasso L, Magnani M, Marincola FM, Wang E, Moretta L, De Maria A.

J Virol. 2017 Nov 14;91(23). pii: e00647-17. doi: 10.1128/JVI.00647-17. Print 2017 Dec 1.

45.

CD56 Is a Pathogen Recognition Receptor on Human Natural Killer Cells.

Ziegler S, Weiss E, Schmitt AL, Schlegel J, Burgert A, Terpitz U, Sauer M, Moretta L, Sivori S, Leonhardt I, Kurzai O, Einsele H, Loeffler J.

Sci Rep. 2017 Jul 21;7(1):6138. doi: 10.1038/s41598-017-06238-4.

46.

MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma.

Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, Locatelli F, Cifaldi L.

Oncoimmunology. 2017 Apr 20;6(6):e1316439. doi: 10.1080/2162402X.2017.1316439. eCollection 2017.

47.

KIR3DS1-Mediated Recognition of HLA-*B51: Modulation of KIR3DS1 Responsiveness by Self HLA-B Allotypes and Effect on NK Cell Licensing.

Carlomagno S, Falco M, Bono M, Alicata C, Garbarino L, Mazzocco M, Moretta L, Moretta A, Sivori S.

Front Immunol. 2017 May 26;8:581. doi: 10.3389/fimmu.2017.00581. eCollection 2017.

48.

Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion.

Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, Rondelli R, Lucarelli B, Brescia LP, Masetti R, Milano GM, Bertaina V, Algeri M, Pinto RM, Strocchio L, Meazza R, Grapulin L, Handgretinger R, Moretta A, Bertaina A, Moretta L.

Blood. 2017 Aug 3;130(5):677-685. doi: 10.1182/blood-2017-04-779769. Epub 2017 Jun 6.

PMID:
28588018
49.

IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Croxatto D, Martini S, Chiossone L, Scordamaglia F, Simonassi CF, Moretta L, Mingari MC, Vacca P.

Oncoimmunology. 2017 Feb 17;6(4):e1293210. doi: 10.1080/2162402X.2017.1293210. eCollection 2017.

50.

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands.

Pesce S, Thoren FB, Cantoni C, Prato C, Moretta L, Moretta A, Marcenaro E.

Front Immunol. 2017 Apr 28;8:510. doi: 10.3389/fimmu.2017.00510. eCollection 2017.

Supplemental Content

Loading ...
Support Center